Down regulation of ADAM33 as a Predictive Biomarker of Aggressive Breast Cancer

Abstract excerpt

Breast cancer is a heterogeneous disease with differences in its clinical, molecular and biological features. Traditionally, immunohistochemical markers together with clinicopathologic parameters are used to classify breast cancer and to predict disease outcome. Triple-negative breast cancer (TNBC) is a particular type of breast cancer that is defined by a lack of expression of hormonal receptors and the HER2...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Breast Cancer Treatment Studies
• Share to Gene expression and cancer classification
• Share to HER2/EGFR in Cancer Research